TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histopathologically confirmed diagnosis of 1 of the following:~  * Acute myeloid leukemia (AML)~ * Myelodysplastic syndromes~    * Intermediate- or high-risk disease~ * Myelofibrosis~ * Granulocytic sarcoma (chloroma)~    * With or without bone marrow involvement~ * Mixed lineage leukemia~    * Induction therapy must have been directed predominantly against AML~ * Acute lymphoblastic leukemia~ * Non-Hodgkin lymphoma~ * Multiple myeloma~* Relapsed or refractory disease with M3 marrow (marrow blasts \> 25%), meeting 1 of the following criteria:~  * Persistent disease after an induction attempt~ * Persistent initial disease after two induction attempts~ * Relapse after one re-induction attempt (second relapse)~ * Persistent disease after first relapse and initial re-induction attempt~* Not eligible for myeloablative allogeneic hematopoietic stem cell transplantation due to age (\> 50 years), organ insufficiency, or significant comorbidity~  * Patients 16-50 years of age must meet ≥ 1 of the following criteria:~    * Ejection fraction 50-60% by MUGA scan and/or echocardiogram~   * DLCO 50-75% of predicted~   * Creatinine clearance or GFR 60-80 mL/min~   * Serum bilirubin ≤ 2.0 mg/dL~   * SGOT and SGPT 1.5-5 times upper limit of normal~   * No other medical and/or psychosocial problem that, in the opinion of the primary physician or principal investigator, would place the patient at unacceptable risk from study regimen~* No Fanconi anemia~* HLA-identical sibling OR matched unrelated donor available~PATIENT CHARACTERISTICS:~* Zubrod or Karnofsky performance status 70-100%~* Negative pregnancy test~* Able to lie supine in a full body cast for 30 minutes~* No HIV infection~* No evidence of active hepatitis B or C infection~* No evidence of cirrhosis~* No uncontrolled viral, bacterial, or fungal infection within the past 4 weeks~* No radiographic changes indicating pulmonary disease (e.g., pulmonary nodules, infiltrates, or pleural effusion) unless cleared by pulmonary biopsy that shows no evidence of active pulmonary disease~* No major medical or psychiatric disorder that would seriously compromise patient tolerance of study regimen~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior radiation therapy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab and Pentostatin In T-cell Neoplasms

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years and older~2. Diagnosis of T lymphoid malignancy established by peripheral blood, bone marrow or tissue (skin, lymph node or other) examination and using the standard criteria.~3. Patients with untreated T-cell-prolymphocytic leukemia (T-PLL), peripheral T-cell lymphoma, hepatosplenic T-cell lymphoma and NK/T cell lymphoma are eligible.~4. Patients with relapsed/refractory T-PLL, T-lineage acute lymphoblastic leukemia (T-ALL), Adult T-cell leukemia/lymphoma (ATLL), peripheral T-cell lymphoma, hepatosplenic T-cell lymphoma and NK/T cell lymphoma and other T-lymphoid malignancies are eligible. Patients who have had prior therapy with either alemtuzumab or pentostatin as single agents are eligible.~5. Willing to use adequate contraception for the entire duration of the study.~6. Performance status 0-2.~7. Creatinine less than or equal to 2.0 mg/dL and calculated creatinine clearance greater than 40~8. Bilirubin less than or equal to 3.0 mg/dL, transaminases (aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT)) less than 4 x upper limit of normal unless related to the disease.~9. Left ventricular ejection fraction greater than 30%.~Exclusion Criteria:~1. Unable or unwilling to sign the consent form.~2. Pregnant or lactating~3. Known to be HIV+~4. Active and uncontrolled infection as judged by treating physician

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab + Pentostatin (Type: EXPERIMENTAL): Alemtuzumab 30 mg intravenous (IV) three times weekly; Pentostatin 4 mg/m\^2 IV weekly for 4 weeks then every 2 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is male or female 18 years of age or older~* Patient is HIV positive~* Patient is naïve to antiretroviral therapy (ART) or has received less than 7 days total of any ART~Extension Study:~* The planned extension study did not take place as the study was terminated after the Week 48 analysis.~Exclusion Criteria:~* Patient is a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence~* Patient has documented resistance to tenofovir or emtricitabine~* Patient is currently participating or has participated in a study with an investigational compound or device within 45 days of signing informed consent~* Patient is pregnant or breastfeeding, or expecting to conceive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Raltegravir 400 mg b.i.d. (Type: ACTIVE_COMPARATOR): None
- Raltegravir 800 mg q.d. (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hemodynamic Effects of Low Dose Spinal Anesthesia for Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult females having elective, repeat cesarean sections who have given informed consent.~Exclusion Criteria:~* • Contraindications to dural puncture~  * BMI \>40~ * Elective C/S presenting in labour or with rupture of membranes~ * Placenta previa or accrete

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose Spinal (Type: EXPERIMENTAL): Hyperbaric bupivacaine 4.5mg with fentanyl 15mcg and preservative free morphine 150mcg.~The patient will be positioned right side down and head down 20-30 degrees for the dural puncture and then positioned supine in the left lateral tilt position after the anesthetic solution has been given. The OR table will be kept in 20-30 degrees head down for the cesarean section.
- Control Spinal Group (Type: ACTIVE_COMPARATOR): Hyperbaric bupivacaine 1.2cc (9mg) with fentanyl 15mcg and preservative free morphine 150mcg.~The patient will be in the sitting position for the dural puncture and then positioned supine, in the left lateral tilt position after the anesthetic solution has been given. Once block height has been established the patient will be placed in 20-30 degrees trendelenberg for the cesarean section.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: NAC for Head Trauma-induced Anosmia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to Ryder Trauma Center for observation acutely following head injury (i.e. concussion), with documented hyposmia or anosmia by University of Pennsylvania Smell Identification Test (SIT).~* Male or female, aged 18 years or older~* Provision of signed and dated informed consent form~* Stated willingness to comply with all study procedures and availability for the duration of the study~* Ability to take oral medication and be willing to adhere to the NAC regimen~* For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of NAC administration~Exclusion Criteria:~* Severe trauma requiring ongoing inpatient treatment beyond 48 hours~* Pregnancy (based on urine screening) or lactation~* Known allergic reactions to components of NAC, such as Mucomyst~* Currently taking nitrates such as nitroglycerine and/or isosorbide regularly~* Currently taking azathioprine (Imuran) or cyclophosphamide (Cytoxan)~* Known diagnosis of cystinuria (renal condition in which cysteine supplement should be avoided)~* Febrile illness within 1 week~* Treatment with another investigational drug or other intervention within 3 months~* Active sinonasal disease by imaging and/or nasal exam, i.e. rhinosinusitis, nasal polyps~* Adults unable to consent~* Prisoners, employees or subordinates~* Individuals who are not yet adults (infants, children, teenagers). This population is excluded because efficacy has not yet been established in adults.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NAC Group (Type: EXPERIMENTAL): NAC group will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days
- Placebo Group (Type: PLACEBO_COMPARATOR): Placebo group will be administered orally as a 4 gram loading dose, followed by 2 g PO BID for 4 days, then 1.5 g PO BID for 2 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EXtended Therapy in Hepatitis C Genotype 3 Infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infected with only genotype 3, hepatitis C~* Treatment naïve before current course of therapy~* A positive HCV RNA test result at Week 4 (no RVR)~* A negative HCV RNA test result at Week 12 (cEVR)~* A recent liver biopsy (within 3 years prior to study entry) is required. If the patient has either liver biopsy proven cirrhosis in the past or has splenomegaly with features of cirrhosis on ultrasound and/or thrombocytopenia (\<150x109/ml) at any time in the past or has a Fibroscan reading of 10 or above or has a Fibrotest score of 0.75 or above (equivalent to F3 on the METAVIR scale), a biopsy will not be required. A copy of the latest report must be available.~Exclusion Criteria:~* Under age 18~* Co-infection with HIV or Hepatitis B or any other HCV genotype in addition to genotype 3~* Prior treatment for Hepatitis C aside from herbal remedies~* Evidence of decompensated liver disease, such as ascites, bleeding varices, hepatic encephalopathy or jaundice (conjugated hyperbilirubinemia)~* INR \> 1.3 at baseline~* Platelet count \<70 X 109/μl at baseline~* Those subjects with diabetes and/or systemic hypertension will need to have ocular examinations (as per standard of care \[SOC\]) prior to treatment and will be excluded if they are found to have a diabetic retinopathy, optic nerve disorders, retinal hemorrhage or any other clinically significant abnormality~* Pre-existing psychiatric conditions including:~  * Current moderate or severe depression despite appropriate therapy.~ * Active suicidal ideation or previous attempt at suicide~ * Patients with a history of severe psychiatric disorder (may be included if so desired by the investigator but pretreatment psychiatric evaluation is required (SOC)).~ * Clinical diagnosis of current substance abuse: Alcohol (\>40g/d), injection drugs, inhalational drugs (not including marijuana), psychotropics, narcotics, cocaine use, prescription or over the counter drugs within one year of the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care treatment (Type: NO_INTERVENTION): Participants will be randomized to receive only the standard 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin).
- Extended therapy (Type: ACTIVE_COMPARATOR): Participants will be randomized to receive 24 weeks of therapy (Peginterferon alfa-2b plus ribavirin) in addition to their standard of care therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Energy Drinks on Cardiovascular Endpoints

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers between ages 18-40 years~* ONLY as needed use of ibuprofen or acetamenophen~* Active duty military~* DoD beneficiary or Civilian Government Employees~Exclusion Criteria:~* No other co-morbid conditions~* No active prescription or OTC drug use~* Not pregnant or planning to become pregnant during study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Energy Drink (Type: EXPERIMENTAL): Energy drink, 2 oz twice daily for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Water, lime juice and cherry flavoring, 2 oz twice daily for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of essential thrombocythemia according to revised World Health Organization (WHO) 2016 criteria.~* Resistant to or intolerant of hydroxyurea, that is, fulfilling at least 1 of the following criteria:~  * Platelet count \> 600 × 10\^9/L after 3 months of at least 2 g/day of hydroxyurea (2.5 g/day in subjects with a body weight over 80 kg) OR at the subject's maximally tolerated dose if that dose is \< 2 g/day.~ * Platelet count \> 400 × 10\^9/L and WBC count \< 2.5 × 10\^9/L or hemoglobin \< 10 g/dL at any dose of hydroxyurea.~ * Presence of leg ulcers or other unacceptable mucocutaneous manifestations at any dose of hydroxyurea.~ * Hydroxyurea-related fever.~* Platelet count ≥ 650 × 10\^9/L at screening.~* WBC ≥ 11.0 × 10\^9/L at screening.~Exclusion Criteria:~* Subjects previously treated with anagrelide or Hydroxyurea (HU).~  1. Prior anagrelide use is allowed provided the reason for discontinuation is not AE-related and anagrelide is stopped at least 28 days before the start of study medications (ie, Day 1).~ 2. Treatment with HU can be stopped at any time once one of the inclusion criteria for HU refractoriness or resistance have been met, and up to the day before the first dose of study treatment (ie, Day 1).~* Inadequate liver function at screening and Day 1 (before drug administration) as demonstrated by:~  * Total bilirubin \> 1.5 × upper limit of normal (ULN)~ * Aspartate aminotransferase or alanine aminotransferase \> 1.5 × ULN~ * Hepatocellular disease (eg, cirrhosis)~* Inadequate renal function at screening as demonstrated by creatinine clearance \< 40 mL/min calculated by Cockcroft-Gault equation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A : Ruxolitinib and anagrelide placebo (Type: EXPERIMENTAL): Ruxolitinib or placebo will be administered orally twice a day at a starting dose of 10 mg.
- Group B : Anagrelide and Ruxolitinib PLacebo (Type: ACTIVE_COMPARATOR): Anagrelide or placebo will be administered orally twice a day at a starting dose of 1 mg. Use of anagrelide will be consistent with approved prescribing information.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
INCLUSION CRITERIA:~A patient will be eligible for inclusion in this study if s/he meets all of the following criteria:~* Has previously undergone BEAC or BEAM autologus SCT with PBSC rescue for any stage aggressive B-cell NHL, including transformed indolent NHL or mantle cell lymphoma according to REAL classification - only B-cell lymphomas are permitted.~* ECOG performance status 0-1.~* Previously histological documented CD20 +NHL.~* Is greater than 18 years of age.~* Is 30-100 days from autologous peripheral blood stem cell transplant.~* Must meet laboratory values (see protocol for values): Absolute neutrophils, hemoglobin and platelets.~* Has a negative serum pregnancy test within 7 days prior to trial registration (only for female patients of childbearing potential).~* If fertile, patient (male or female) has agreed to use physician-approved method of birth control to avoid pregnancy for the duration of the study and for a period of 3 months thereafter.~* Has signed a Patient Informed Consent Form.~* Has signed a Patient Authorization Form (HIPAA).~EXCLUSION CRITERIA:~Patients will be taken off treatment if any of the following occur:~* ECOG PS \>2.~* A history of hypersensitivity to study drugs, or any component thereof, or anaphylactic history to murine protein.~* Manifested cardiac complications during transplant, including arrthymias, congestive heart failure, angina, or myocardial infarct, or had a decreased LVEF to \<45% prior to transplant~* On systemic corticosteroids.~* Diffusion capacity \<60% (corrected) and has decreased 30% or more following transplant~* Documented disease progression (See Section 10.1.6 for definition).~* Active infection, and/or is known to be seropositive for hepatitis B, hepatitis C, or HIV~* Pericardial effusion, pleural effusions, or ascites.~* A history of very aggressive NHL, such as Burkitt's or atypical Burkitt's lymphoma~* Receiving concurrent immunotherapy or rituximab therapy.~* Previously received a solid organ transplant.~* History of CNS involvement.~* A serious uncontrolled intercurrent medical or psychiatric illness, including serious infection~* A history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs.~* A pregnant or nursing woman.~* Unable to comply with requirements of study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ALF-STONE: Alfuzosin in Uretheric Stones

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Patients with imagiologic evidence of uretheric stones~Exclusion criteria:~* Women pregnant or breast feeding~* Patients with renal impairment (creatinine \> 2mg/dl)~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Goal of Open Lung Ventilation in Donors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Brain death~* Authorization for research~* ≥13 years of age~Exclusion Criteria:~* Arterial/Inspired oxygen ratio (PaO2/FiO2) ≤ 150 mmHg~* PaO2/FiO2 ≥ 400 mmHg~* BMI \> 40~* Hepatitis B surface antigen positive~* Hepatitis C positive~* Failure to complete donation process~* Hemodynamic instability

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open Lung Protective Ventilation (Type: EXPERIMENTAL): Volume cycled assist control ventilation with tidal volume 8 cc/kg predicted body weight, PEEP 10 cm water (H2O), recruitment maneuvers every 8 hours and after any ventilator disconnect
- Conventional Ventilation (Type: ACTIVE_COMPARATOR): Volume cycled assist control ventilation with tidal volume 10 cc/kg predicted body weight, PEEP 5 cm H2O, recruitment maneuvers after any ventilator disconnect

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility